Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Moderna

Pfizer COVID shot works, safe for youngest kids, FDA says

U.S. Food and Drug Administration staff said that Pfizer Inc.’s COVID-19 shot was effective for kids ages 4 and under with no new safety concerns, in a report released ahead of a key meeting of FDA advisers later this week.

Tribune News Service

US: Pfizer COVID-19 appears effective for kids under 5

A review by federal health officials says that Pfizer's COVID-19 vaccine appears safe and effective for children under 5, the only group not currently eligible for vaccination

The Independent UK

Research on a deadly bacteria might be a COVID-19 vaccine gamechanger

The Covid-19 pandemic, being truly global, created the demand for vaccines, such as the now-familiar ones from Pfizer, Moderna and AstraZeneca.

Inverse

From analysis to the latest developments in health,
read the most diverse news in one place.

US health authority says Moderna vaccine effective in under-fives

Washington (AFP) - US health authorities confirmed on Friday that data provided by drug-maker Moderna on the efficacy of its Covid-19 vaccine among very young children were accurate, ahead of a decision next week on whether to authorize two inoculations against the virus in kids aged six months to five…

AFP

Marathon US hearings to decide fate of COVID shots for tots

Next week brings a marathon of hearings as the U.S. decides whether to open COVID-19 vaccinations to kids under 5

The Independent UK

Why Moderna Stock Is Moving Lower Today

Moderna Inc (NASDAQ: MRNA) shares are trading lower Thursday as vaccine stocks fall in sympathy with Novavax Inc (NASDAQ: NVAX) following reports the FDA's decision on the company's COVID-19 vacci

Benzinga

Novavax Dive Continues As FDA Reviews New Covid Shot Information

Three days after the FDA's advisors recommended Novavax's Covid shot, the agency had yet to make a move, and NVAX stock toppled.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

US Schedules Covid-19 Vaccines For Children Below Five Years

The U.S. government is preparing to launch vaccines for children below five in conjunction with educational and outreach efforts, pending approval by federal regulators, the Wall Street Journal reports. The government looks to provide ten million initial doses as the virus spreads nationwide, leaving the parents anxious. The vaccinations could begin…

Benzinga

Cathie Wood Trims Pfizer Stake And Loads Up $25M In Rival COVID-19 Vaccine Maker

Cathie Wood led Ark Invest on Wednesday initiated a position in Moderna Inc (NASDAQ: MRNA) after the biotech company said an updated version of its COVID-19 booster vaccine appeared to provide strong

Benzinga

Trials of new COVID vaccine raise hopes of once-a-year booster

Moderna shot is said to produce eightfold increase in antibody levels against Omicron in first four weeks

The Guardian - UK

Moderna Climbs On Updated Booster Data, But Analyst Says It Needs A 'Second Act'

Moderna stock popped Wednesday after its updated Covid booster generated a strong antibody response against the omicron variant.

Investors Business Daily

Moderna vaccine trial raises hopes of yearly Covid booster

People who received vaccine showed significant jump in antibody levels compared to original Moderna jab

The Independent UK

Moderna’s omicron-targeted shot bolsters antibodies in trial

Moderna Inc. said its COVID-19 vaccine that targets omicron generated a “superior” immune response against the variant compared to its original shot in a widely awaited study that could pave the way for another round of boosters in the fall.

Tribune News Service

Moderna's Updated COVID-19 Shot Boosts Omicron Protection

Moderna Inc (NASDAQ: MRNA) has

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Axios

Moderna booster update for Omicron variant could be available late summer

The booster contains the original vaccine with an updated version that specifically targets the Omicron variant.

AFP

Moderna announces positive results for Omicron vaccine

Washington (AFP) - US biotech company Moderna on Wednesday announced positive results for a new vaccine that targets both the original Covid strain and Omicron, and sees the shot as its "lead candidate" for a booster this fall.

Investors Business Daily

8 Big Growth Stocks Are Now Even Cheaper Than 'Value' Stocks

Looking for a sign of how far the wipeout of S&P 500 growth stocks has gone? Consider this: Some growth stocks are now cheaper than value stocks.

Benzinga

What's Next For Novavax Stock As COVID Vaccine Clears Key Hurdle In US

After last week's scare stirred by the release of the Food And Drug Administration's briefing documents, Novavax (NASDAQ: NVAX) can now heave a sigh of relief.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Moderna announces promising results from next-generation Covid vaccine trials

Experts hope the newer jabs could protect against a wider range of variants.

WEKU

Moderna says its new vaccine booster shows 'superior' response to omicron

The "bivalent" vaccine — meaning it targets two different antigens — is Moderna's leading candidate for an effective booster this fall. If the data pan out, it could lead to a yearly booster.

The Independent UK

Moderna says updated COVID shot boosts omicron protection

Moderna says its experimental COVID-19 vaccine that combines its original shot with protection against the omicron variant appears to work

Asharq Al-Awsat

Moderna Says Omicron-Specific Booster Generates Strong Immune Response

Moderna Inc said on Wednesday its COVID-19 vaccine booster that targets both the original coronavirus strain and Omicron produced a better immune response against the variant than its original vaccine. The booster raised virus-neutralizing antibodies by eight-fold in a study.

Reuters

Moderna says Omicron-targeted COVID shot shows better response

Moderna Inc said on Wednesday a new version of its coronavirus vaccine produced a better immune response against Omicron than the original shot, as the drugmaker pursues a booster against a surge in infections in the fall season.

Investors Business Daily

Novavax Stock Jumps After FDA Advisors Endorse Its Covid Shot

An FDA panel voted nearly unanimously in favor of Novavax's Covid shot on Tuesday. After yo-yoing Wednesday, NVAX stock settled up.

Benzinga

Expert Ratings for Moderna

Within the last quarter, Moderna (NASDAQ:MRNA) has observed the following analyst ratings:

1 … 24 25 26 27

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.